Stock 000513 LIVZON PHARMACEUTICAL GROUP INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Livzon Pharmaceutical Group Inc.

Equities

000513

CNE0000002Y8

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
38.98 CNY -1.32% Intraday chart for Livzon Pharmaceutical Group Inc. +2.99% +11.34%
Apr. 26 Livzon Pharmaceutical Factory Receives Approval for the U.S. FDA Approval for the Company's Drug Cetrorelix Acetate for Injection CI
Apr. 24 Livzon Pharmaceutical's Q1 Profit Jumps 4.5%; Revenue Slips 5% MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 27,656 33,157 32,307 27,456 28,292 31,443 - -
Enterprise Value (EV) 1 20,161 25,123 25,850 20,652 21,099 24,784 25,590 24,329
P/E ratio 24.2 x 22.1 x 21.2 x 15.9 x 16.7 x 16.8 x 14.8 x 14.1 x
Yield 3.41% 3.09% 3.23% 4.93% 3.86% 4.14% 4.72% 5.27%
Capitalization / Revenue 2.95 x 3.15 x 2.68 x 2.17 x 2.28 x 2.37 x 2.17 x 2.11 x
EV / Revenue 2.15 x 2.39 x 2.14 x 1.64 x 1.7 x 1.87 x 1.77 x 1.64 x
EV / EBITDA 9.54 x 9.96 x 10.6 x 6.85 x 5.85 x 8.08 x 7.58 x 6.54 x
EV / FCF 14,705,388 x 16,540,506 x - - - - - -
FCF Yield 0% 0% - - - - - -
Price to Book 2.82 x 3.16 x 2.84 x 2.19 x 2.3 x 2.41 x 2.29 x 2.21 x
Nbr of stocks (in thousands) 934,763 938,721 934,387 933,588 923,938 922,299 - -
Reference price 2 33.70 40.50 40.21 32.48 35.01 38.98 38.98 38.98
Announcement Date 3/25/20 3/22/21 3/28/22 3/30/23 3/28/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 9,385 10,520 12,064 12,630 12,430 13,283 14,457 14,868
EBITDA 1 2,114 2,522 2,431 3,014 3,605 3,069 3,375 3,721
EBIT 1 1,730 2,500 2,267 2,351 2,415 2,681 2,921 3,014
Operating Margin 18.43% 23.77% 18.79% 18.61% 19.43% 20.19% 20.21% 20.27%
Earnings before Tax (EBT) 1 1,728 2,489 2,246 2,331 2,383 2,765 3,047 3,177
Net income 1 1,303 1,715 1,776 1,909 1,954 2,156 2,430 2,503
Net margin 13.88% 16.3% 14.72% 15.12% 15.72% 16.23% 16.81% 16.84%
EPS 2 1.390 1.830 1.900 2.040 2.100 2.318 2.635 2.767
Free Cash Flow 1,371 1,519 - - - - - -
FCF margin 14.61% 14.44% - - - - - -
FCF Conversion (EBITDA) 64.84% 60.22% - - - - - -
FCF Conversion (Net income) 105.23% 88.57% - - - - - -
Dividend per Share 2 1.150 1.250 1.300 1.600 1.350 1.612 1.841 2.055
Announcement Date 3/25/20 3/22/21 3/28/22 3/30/23 3/28/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 2,695 3,479 2,824 3,186 3,141 3,413 3,277 2,965 2,775 3,243 3,458 3,384 3,112 3,529
EBITDA - - - - - - - - - - - - - -
EBIT 1 392.1 723.5 601.7 547.5 477.9 738.3 690.1 558.8 427.9 757.9 725.7 603.7 538.2 842
Operating Margin 14.55% 20.8% 21.31% 17.18% 15.21% 21.63% 21.06% 18.85% 15.42% 23.37% 20.99% 17.84% 17.29% 23.86%
Earnings before Tax (EBT) - - - - - - - - - - - - - -
Net income - - - - - - - - - - - - - -
Net margin - - - - - - - - - - - - - -
EPS 2 0.3500 0.5900 0.5000 0.5200 0.4300 0.6200 0.6000 0.5000 0.3800 0.6500 0.5300 0.5300 0.5200 0.6800
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 3/28/22 4/21/22 8/9/22 10/25/22 3/30/23 4/20/23 8/23/23 10/24/23 3/28/24 4/23/24 - - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 7,495 8,034 6,457 6,804 7,193 6,659 5,853 7,115
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1,371 1,519 - - - - - -
ROE (net income / shareholders' equity) 12% 14.9% 14.1% 14.3% 14% 15.1% 16% 15.9%
ROA (Net income/ Total Assets) 7.36% 8.89% 8.27% 8.08% 7.83% 8.6% 8.95% 9.3%
Assets 1 17,707 19,284 21,482 23,619 24,957 25,064 27,150 26,918
Book Value Per Share 2 11.90 12.80 14.20 14.80 15.20 16.20 17.00 17.70
Cash Flow per Share 2 1.890 2.290 2.030 2.960 3.520 3.050 2.840 -
Capex 1 396 642 1,300 937 806 961 903 1,030
Capex / Sales 4.22% 6.1% 10.78% 7.42% 6.48% 7.23% 6.25% 6.93%
Announcement Date 3/25/20 3/22/21 3/28/22 3/30/23 3/28/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Livzon Pharmaceutical Group Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
38.98 CNY
Average target price
40.8 CNY
Spread / Average Target
+4.68%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
LIVZON PHARMACEUTICAL GROUP INC. Stock Livzon Pharmaceutical Group Inc.
+11.34% 4.34B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 000513 Stock
  4. Financials Livzon Pharmaceutical Group Inc.